LSV Asset Management Grows Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

LSV Asset Management grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 27.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 640,950 shares of the medical equipment provider's stock after purchasing an additional 139,647 shares during the quarter. LSV Asset Management owned approximately 0.92% of Lantheus worth $51,462,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LNTH. Torray Investment Partners LLC boosted its holdings in Lantheus by 6.4% in the second quarter. Torray Investment Partners LLC now owns 26,078 shares of the medical equipment provider's stock valued at $2,094,000 after purchasing an additional 1,560 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Lantheus by 24.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 52,864 shares of the medical equipment provider's stock valued at $4,244,000 after buying an additional 10,388 shares in the last quarter. UNIVEST FINANCIAL Corp grew its position in shares of Lantheus by 37.9% in the 2nd quarter. UNIVEST FINANCIAL Corp now owns 5,528 shares of the medical equipment provider's stock valued at $444,000 after buying an additional 1,519 shares during the last quarter. Foundry Partners LLC acquired a new stake in Lantheus during the 2nd quarter worth $488,000. Finally, Arizona State Retirement System lifted its position in Lantheus by 2.0% in the second quarter. Arizona State Retirement System now owns 19,190 shares of the medical equipment provider's stock valued at $1,541,000 after acquiring an additional 368 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Leerink Partners lifted their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. Finally, JMP Securities cut their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $126.00.

Insider Transactions at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the transaction, the chief accounting officer now owns 62,557 shares of the company's stock, valued at $4,990,171.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The disclosure for this sale can be found here. In the last three months, insiders sold 41,193 shares of company stock valued at $3,949,202. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Performance

LNTH traded down $1.52 during trading on Tuesday, hitting $99.08. The stock had a trading volume of 548,033 shares, compared to its average volume of 1,031,282. The firm has a market capitalization of $6.88 billion, a P/E ratio of 15.13 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company's 50-day moving average price is $103.44 and its 200 day moving average price is $82.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the firm earned $1.40 earnings per share. The company's revenue was up 22.5% compared to the same quarter last year. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.